ProQR Therapeutics NV (NASDAQ:PRQR)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $5.90, but opened at $5.94. ProQR Therapeutics NV shares last traded at $6.00, with a volume of 11,663 shares changing hands.

PRQR has been the subject of several recent analyst reports. Zacks Investment Research lowered ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a report on Saturday, August 20th. Leerink Swann reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Finally, Chardan Capital initiated coverage on ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. ProQR Therapeutics NV currently has a consensus rating of “Hold” and an average target price of $15.94.

The firm’s 50-day moving average is $5.05 and its 200 day moving average is $4.91. The stock’s market capitalization is $131.44 million.

ProQR Therapeutics NV (NASDAQ:PRQR) last released its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. On average, equities research analysts predict that ProQR Therapeutics NV will post ($2.14) EPS for the current year.

A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Jennison Associates LLC boosted its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 3.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,001,774 shares of the biopharmaceutical company’s stock after buying an additional 33,019 shares during the period. Jennison Associates LLC owned approximately 4.29% of ProQR Therapeutics NV worth $8,695,000 at the end of the most recent reporting period.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.